Trial Profile
Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy w/ Adenoviral & Yeast-based Vaccines to Induce T-cell Responses in Subjects w/ Advanced, Unresectable & Untransplantable HCC
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Aldoxorubicin (Primary) ; Avelumab (Primary) ; Brachyury peptide vaccine (Primary) ; Capecitabine (Primary) ; Cetuximab (Primary) ; ETBX 011 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; GI 4000 (Primary) ; GI 6207 (Primary) ; High affinity CD-expressing natural killer cell therapy ImmunityBio (Primary) ; Nogapendekin alfa inbakicept (Primary) ; Paclitaxel (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms QUILT-3.072
- Sponsors NantKwest
- 23 Aug 2019 Planned End Date changed from 30 Dec 2022 to 23 Aug 2019.
- 23 Aug 2019 Planned primary completion date changed from 30 Jul 2020 to 23 Aug 2019.
- 23 Aug 2019 Planned initiation date changed from 29 Jun 2018 to 25 May 2018.